Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XORTX Therapeutics Inc. (XRTX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. XORTX files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These filings furnish investors with information on financial performance, clinical and regulatory progress, securities offerings, and material corporate developments related to the company’s gout and kidney disease programs.
Recent Form 6-K submissions have included condensed interim consolidated financial statements, management discussion and analysis, and officer certifications, as well as press releases describing registered direct offerings, private placements, Nasdaq minimum bid price notifications, and the binding term sheet to acquire the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited. Certain 6-K exhibits, such as legal opinions on the validity of securities, are incorporated by reference into XORTX’s shelf registration statement on Form F-3 (File No. 333-269429).
Through this page, users can review key filing types relevant to XORTX’s sector, including 6-K reports detailing clinical and regulatory updates for the XRx-026 gout program and related XORLO™ formulation, as well as financing structures involving common shares, pre-funded warrants, and agent warrants. The filings also document the company’s responses to Nasdaq listing requirements and its use of at-the-market and registered offerings to fund development of gout, ADPKD, acute kidney injury, and diabetic nephropathy programs.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Real-time updates from EDGAR, along with structured access to XORTX’s 6-K reports and other registered offerings, help investors quickly understand how regulatory events, financings, and clinical disclosures affect the company’s xanthine oxidase–targeted pipeline.
XORTX Therapeutics Inc. filed a Post-Effective Amendment to its Form F-1 registering up to 2,202,643 common shares or up to 2,202,643 pre-funded warrants, using an assumed offering price of $2.27 per share. The company estimates approximately $4.7 million of net proceeds (assuming sale of all Shares and no pre-funded warrants), which it expects to use for research and development, working capital and general corporate purposes, including up to $2.0 million to IR Agency LLC for investor relations activities. The filing notes a recent 5-for-1 share consolidation (effective April 6, 2026) and the April 13, 2026 acquisition of Vectus assets for $3.0 million paid via 154,544 common shares and 692,150 pre-funded warrants.
XORTX Therapeutics is offering up to 2,202,643 common shares (or up to 2,202,643 pre-funded warrants in lieu of shares) in a primary offering under a post-effective amendment to its Form F-1. The prospectus uses an assumed public offering price of $2.27 per share and states the company expects approximately $4.7 million of net proceeds based on that price and assuming no sale of pre-funded warrants. The offering includes ownership limits that permit certain purchasers to elect pre-funded warrants to avoid exceeding 4.99% (or, if elected, 9.99%) beneficial ownership thresholds. Shares outstanding were 2,239,137 as of April 17, 2026. The Placement Agent is E.F. Hutton & Co. and the placement will be conducted on a reasonable best efforts basis.
XORTX Therapeutics Inc. reports that it has regained compliance with Nasdaq’s continued listing rules for the minimum bid price. Nasdaq requires shares to maintain a bid of at least US$1.00 per share for 10 consecutive trading days. After a 1-for-5 reverse split of its common shares on April 6, 2026, this requirement was met on April 17, 2026, and XORTX received a Nasdaq compliance letter on April 20, 2026, curing the prior deficiency.
XORTX Therapeutics has closed the acquisition of Vectus Biosystems’ VB4-P5 kidney anti-fibrotic program for total consideration of US$3.0 million. The deal adds a pre-IND small-molecule candidate targeting kidney fibrosis in both rare and common chronic kidney diseases, an area with significant unmet need.
As payment, XORTX issued 154,544 common shares and 692,150 pre-funded warrants, each warrant exercisable at US$0.0001 and capped so Vectus cannot own more than 9.99% of XORTX’s common shares. The warrants expire on April 13, 2031, and the TSX Venture Exchange has conditionally approved listing all shares issuable under the transaction.
XORTX Therapeutics Inc. filed a Form 6-K confirming the effective details of its previously announced share consolidation. The consolidation will occur on April 6, 2026, on the basis of one new common share for every five old common shares, following approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The company is a late-stage clinical pharmaceutical business with three clinically advanced programs targeting gout and progressive kidney diseases, plus an additional pre-clinical program for Type 2 diabetic nephropathy.
XORTX Therapeutics Inc. reported the results of its annual and special shareholder meeting held on March 24, 2026. Shareholders representing 2,407,148 common shares, approximately 35% of the shares outstanding, were present.
All items on the agenda were approved, including the election of five management nominees to the board, re-appointment of Davidson & Company LLP as auditors with directors authorized to set their pay, re-approval of the stock option plan and approval of a share consolidation.
XORTX Therapeutics Inc. reported shareholder voting results from its annual general and special meeting held on March 24, 2026. Shareholders approved setting the board at five directors and elected all nominees with strong support, including several at 100% of votes cast.
They reappointed Davidson & Co. LLP as auditor and re‑approved the stock option plan, which reserves up to 10% of issued and outstanding common shares at the grant date. Shareholders also authorized a share consolidation of up to 5 pre‑consolidation shares for 1 post‑consolidation share to help the company regain compliance with NASDAQ Capital Market continued listing requirements.
XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation. The company now expects the 1-for-5 consolidation of its common shares to take effect on April 6, 2026 instead of March 27, 2026, and it remains subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout, autosomal dominant polycystic kidney disease, and kidney injury related to respiratory virus infections.
XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation. The company now expects the 1-for-5 consolidation of its common shares to take effect on April 6, 2026 instead of March 27, 2026, and it remains subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout, autosomal dominant polycystic kidney disease, and kidney injury related to respiratory virus infections.
XORTX Therapeutics Inc. is carrying out a share consolidation, exchanging one new common share for every five existing shares to help maintain its Nasdaq listing. This 1‑for‑5 consolidation will reduce issued and outstanding shares from 6,962,218 to approximately 1,392,444.
The company will keep its current name, and its stock will continue trading on the TSX Venture Exchange and Nasdaq under the symbol XRTX on a post‑consolidation basis with a new CUSIP. All convertible securities will be proportionately adjusted, and fractional shares will be cancelled or rounded up without any cash payments.
XORTX Therapeutics Inc. reports that shareholders have approved a share consolidation, authorizing the board to combine up to five existing common shares into one new common share. The board may implement this consolidation within one year of the March 24, 2026 meeting, subject to TSX Venture Exchange approval.
The company states the primary purpose is to help maintain compliance with Nasdaq’s continued listing requirements that its shares trade above $1.00, including a condition that they trade above $1.00 for 10 days by April 13, 2026. XORTX currently has 6,962,218 common shares outstanding, which would become approximately 1,392,443 post-consolidation, depending on the treatment of fractional shares. No name change will occur, and fractional holdings will be cancelled or rounded up according to set thresholds.